Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study

被引：0

作者：

von Amsberg, G. ^{[1
]}

Powles, T. ^{[2
]}

Loriot, Y. ^{[3
]}

Ravaud, A. ^{[4
]}

Vogelzang, N. J. ^{[5
]}

Duran, I. ^{[6
]}

Retz, M. ^{[7
]}

De Giorgi, U. ^{[8
]}

Oudard, S. ^{[9
]}

Bamias, A. ^{[10
]}

Koeppen, H. ^{[11
]}

Leng, N. ^{[11
]}

Kadel, E. E. ^{[11
]}

Hegde, P. S. ^{[11
]}

Cui, N. ^{[11
]}

Shen, X. ^{[11
]}

Green, M. ^{[11
]}

Banchereau, R. ^{[11
]}

Mariathasan, S. ^{[11
]}

van der Heijden, M. S. ^{[12
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Ctr Oncol, Hamburg, Germany

[2] Queen Mary Univ London, Barts Canc Inst, London, England

[3] Gustave Roussy, Villejuif, France

[4] Hop St Andre CHU, Bordeaux, France

[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[6] Univ Seville, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio, CSIC, Seville, Spain

[7] Tech Univ Munich, Munich, Germany

[8] IRST IRCCS, Meldola, Italy

[9] Hop Europeen Georges Pompidou, Paris, France

[10] Univ Athens, ALEXANDRA Hosp, Athens, Greece

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Netherlands Canc Inst, Amsterdam, Netherlands

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P990

引用

页码：325 / 326

页数：2

共 42 条

[41] IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto, M.
Zvirbule, Z.
Alvarez, R.
Chewaskulyong, B.
Baranda, L. A. Herraez
Shearer-Kang, E.
Liu, X.
Tosti, N.
Sanchez, A. Y. Castro
Zanghi, J.
Felip, E.
ANNALS OF ONCOLOGY, 2023, 34
[42] Phase II, multicenter, randomized, open-label, parallel-arm, umbrella study JAVELIN Bladder Medley of avelumab (MSB0010718C) in combination with sacituzumab govitecan, M6223 and NKTR-255 as maintenance therapy in participants with locally advanced or metastatic urothelial carcinoma treated with first-line platinum-containing therapy (1L) chemotherapy has not progressed. - JAVELIN Bladder Medley - AB 88/23 from AUO
Rexer, Heidrun
Banek, Severine
Merseburger, Axel S.
AKTUELLE UROLOGIE, 2023, 54 (06) : 438 - 440

← 1 2 3 4 5 →